In vivo anticancer activity of lysates from trypanosoma cruzi of different genetic groups

Area of Science:

• Parasitology
• Immunology
• Oncology

Background:

• Trypanosoma cruzi is a protozoan parasite.
• Ehrlich adenocarcinoma is a type of mouse tumor.
• Investigating non-toxic anti-cancer agents is crucial.

Purpose of the Study:

• To evaluate the anti-tumor potential of Trypanosoma cruzi epimastigote lysates against Ehrlich adenocarcinoma in mice.
• To determine the dose-dependency and clone-specificity of the anti-tumor effect.
• To assess the toxicity of the parasite lysates.

Main Methods:

• Preparation of epimastigote lysates from various Trypanosoma cruzi clones.
• Administration of daily injections of parasite lysates to mice bearing Ehrlich adenocarcinoma.
• Monitoring tumor growth and assessing the protective effect over time.
• Evaluating the toxicity of the lysates at studied doses.

Main Results:

• Lysates from multiple Trypanosoma cruzi clones demonstrated significant inhibition of Ehrlich adenocarcinoma growth.
• Tumor volume decreased by 1.5-3 times following 12 daily injections of 15 million epimastigote equivalents.
• The anti-tumor effect persisted and even progressed after the cessation of injections.
• The observed protective effect was dependent on both the dosage and the specific Trypanosoma cruzi clone used.
• The parasite lysates exhibited no toxicity at the tested concentrations.

Conclusions:

• Trypanosoma cruzi epimastigote lysates possess potent anti-tumor properties against Ehrlich adenocarcinoma.
• The anti-cancer activity is clone-specific and dose-dependent, suggesting a targeted therapeutic potential.
• These findings highlight Trypanosoma cruzi lysates as a promising, non-toxic candidate for further investigation in cancer therapy.